Aprea Therapeutics, Inc.
APRE
$1.84
-$0.0799-4.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.26% | 157.60% | 130.31% | 410.93% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.26% | 157.60% | 130.31% | 410.93% | -- |
| Cost of Revenue | 28.54% | 22.76% | 48.04% | 63.00% | -17.97% |
| Gross Profit | -27.89% | -11.60% | -39.60% | -45.12% | 27.88% |
| SG&A Expenses | -9.98% | -23.36% | -21.06% | -30.42% | -71.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.54% | -1.45% | 7.07% | 0.61% | -55.89% |
| Operating Income | -8.97% | 7.45% | -2.21% | 6.16% | 58.73% |
| Income Before Tax | -10.73% | 9.30% | -1.67% | 8.35% | 88.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.73% | 9.30% | -1.67% | 8.35% | 88.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.73% | 9.30% | -1.67% | 8.35% | 88.34% |
| EBIT | -8.97% | 7.45% | -2.21% | 6.16% | 58.73% |
| EBITDA | -8.92% | 7.55% | -2.08% | 6.27% | 58.76% |
| EPS Basic | 28.85% | 40.52% | 29.63% | 44.46% | 96.36% |
| Normalized Basic EPS | 28.85% | 40.52% | 29.63% | 44.46% | 86.28% |
| EPS Diluted | 28.85% | 40.52% | 29.63% | 44.46% | 96.36% |
| Normalized Diluted EPS | 28.85% | 40.52% | 29.63% | 44.46% | 86.28% |
| Average Basic Shares Outstanding | 54.69% | 52.31% | 48.11% | 54.80% | 75.51% |
| Average Diluted Shares Outstanding | 54.69% | 52.31% | 48.11% | 54.80% | 75.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |